Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Pediatr. Dec 9, 2025; 14(4): 108520
Published online Dec 9, 2025. doi: 10.5409/wjcp.v14.i4.108520
Published online Dec 9, 2025. doi: 10.5409/wjcp.v14.i4.108520
Research on gamma globulin unresponsive Kawasaki disease: A review
Zu-Chuang Wu, Yan Pan, Department of Pediatrics, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China
Zu-Chuang Wu, Department of Pediatics, The Fifth Central Hospital of Tianjin, Tianjin 300450, China
Author contributions: Wu ZC performed research, analyzed data, and wrote the paper; Pan Y designed research, contributed new analytic tools, and modify the paper; Both authors participated in manuscript revision and communication with editors.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Pan, Researcher, Department of Pediatrics, The First Affiliated Hospital of Yangtze University, No. 55 Jianghan North Road, Shashi District, Jingzhou 434000, Hubei Province, China. woshipanyan@126.com
Received: April 17, 2025
Revised: May 14, 2025
Accepted: August 13, 2025
Published online: December 9, 2025
Processing time: 197 Days and 20.6 Hours
Revised: May 14, 2025
Accepted: August 13, 2025
Published online: December 9, 2025
Processing time: 197 Days and 20.6 Hours
Core Tip
Core Tip: Gamma globulin-unresponsive Kawasaki disease (KD) poses significant clinical challenges due to its complex pathophysiology and variable treatment outcomes. This review synthesizes current knowledge on epidemiology, intravenous immunoglobulin resistance mechanisms, diagnostic criteria, and evolving therapeutic strategies (e.g., corticosteroids, biologics). Key controversies include optimal second-line therapies and long-term cardiovascular monitoring. Future di
